Budapest, Hungary

Istvan Rakoczi

This inventor holds 1 USPTO granted patent. Top assignee: Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.. Active years: 1984.


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1984

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Istvan Rakoczi

Introduction

Istvan Rakoczi is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceuticals, particularly in the development of prostaglandin derivatives. His work has led to advancements that may have important implications for medical treatments.

Latest Patents

Rakoczi holds a patent for "2,3,4-Trinor-m-inter-phenylene-prostaglandin derivatives and 2,3,4-trinor-1,5-inter-m-phenylene-prostacycline derivatives." This patent includes a formula where R¹ can be hydrogen, a C₁-4 alkyl group, an alkali metal cation, or a primary, secondary, tertiary, or quaternary ammonium cation. His innovative approach in this area showcases his expertise and dedication to advancing pharmaceutical science.

Career Highlights

Rakoczi is associated with Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt., a company known for its contributions to the pharmaceutical industry. His role there has allowed him to focus on research and development, leading to his patent and furthering the company's mission in healthcare.

Collaborations

Throughout his career, Rakoczi has collaborated with notable colleagues such as Sandor Botar and Peter S Kormoczy. These partnerships have likely enriched his research and contributed to the success of his innovations.

Conclusion

Istvan Rakoczi's work exemplifies the impact of dedicated inventors in the pharmaceutical field. His patent and collaborations highlight the importance of innovation in developing new medical treatments. His contributions continue to influence the industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…